Invest in MJ Blog

Invest In MJ is a multi-author and community member blog. Read the latest blogs about investment ideas in the marijuana and cannabis industry.

  • Home
    Home This is where you can find all the blog posts throughout the site.
  • Categories
    Categories Displays a list of categories from this blog.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Bloggers
    Bloggers Search for your favorite blogger from this site.
  • Team Blogs
    Team Blogs Find your favorite team blogs here.
  • Archives
    Archives Contains a list of blog posts that were created previously.
  • Login
    Login Login form

The support for cannabis legalization by the public is stronger today than over the last few decades.  However, most non-cannabis users still believe the old stereotype about "stoners" — that marijuana smokers are apathetic, unsuccessful, flaky… and the list goes on.

But, contrary to the popular stereotype which is based mostly on miss-information or lack of research, there is a new study which suggests they are in fact among the most satisfied and successful among us.  

As it turns out, cannabis consumers are among the most well-adjusted and successful of American adults, based on results from BDS Analytics’ landmark cannabis consumer research study.

The study surveyed consumers (acceptors) and abstainers (rejecters) across a wide variety of mental, social and financial factors. The survey analysed extensive data from two US states that have voted to legalise the sale of cannabis -California and Colorado.

Among the findings, Cannabis Consumers are: 

Accomplished Personally and Professionally

  • Average annual household income among California Consumers is $93,800, compared to $72,800 for Acceptors and $75,900 for Rejecters.
  • The percentage of people holding master’s degrees among California Consumers is 20 percent, compared to 13 percent for Acceptors and 12 percent for Rejecters.
  • Full-time employment is enjoyed by 64 percent of Colorado Consumers, compared to 51 percent of Acceptors and 54 percent of Rejecters.

Satisfied with Life

  • Nearly five in 10 Colorado Consumers agree they are more satisfied with life today than they were a year ago, compared to about four in 10 among Acceptors and Rejecters.

Parents Raising Families

  • Cannabis Consumers are the most likely segment to be parents in California: 64 percent of Consumers are parents, compared to 60 percent of Acceptors and 55 percent of Rejecters.
  • In addition, Consumers in California are significantly more likely to have children ages 10 years or younger at home — 37 percent of Consumers compared to 23 percent of Acceptors and 11 percent of Rejecters

Active Socially and Creatively

  • Among Colorado Consumers, 36 percent agree they are very social people, compared to 21 percent for Acceptors and 28 percent for Rejecters.
  • Acceptors in Colorado were more likely to enjoy the fine arts and describe themselves as creative.

Enjoy the Outdoors

  • When compared to Rejecters, Consumers in both Colorado and California say they enjoy outdoor recreation at a higher rate — 50 percent for Colorado Consumers compared to 36 percent for Colorado Rejecters, and 57 percent for California Consumers compared to 26 percent for California Rejecters.

Nurturing and Volunteers

  • In California, 60 percent of Consumers agree that they are nurturing people, compared to 41 percent of Rejecters. Also, 38 percent of Consumers say they volunteer their time to help others, compared to 25 percent of Rejecters.

The following is a comment from Linda Gilbert, head of the consumer research division at BDS: “Cannabis consumers are far removed from the caricatures historically used to describe them”.

Public support for cannabis legalization is at an all-time high, the misconception and myths around cannabis users is clearly debunked from this study.  We are thankful that real insight and studies are now being done around cannabis. Over the years we expect this trend to continue and more light will be shed on the benefits of cannabis use.  This will hopefully shatter the misconceptions and false information typically cited by people who are anti-cannabis.  The tides are turning and the truth is being shared, that is a positive step forwards towards the legalization of cannabis.

See full report and details about BDS Analytics. June 6 2017

Rate this blog entry:
0

Invest In MJ News (#IMJ) Update for March 15 2017

As we mentioned a few days ago, we are in a healthy correction in the Cannabis sector for stock price and valuations.  In Canada, the valuations of the licensed producers have gotten way ahead of itself over the last few months; they should start to build a base during the summer before moving higher going into fall and winter of 2018.

Looks like the sector will move sideways for some time, this creates a good trading opportunity, new entry points for new positions or adding to existing positions.  Sign up for our newsletter to get more ideas on investing and trading the MJ Stocks.

One of the companies we provide coverage on is Emblem Cannabis, the chart below is some initial technical analysis we provide as part of our research.  You can view price charts and company info on Emblem from our company directory.  Our latest news letter provides more details on Emblem, investment and trading strategies. 

b2ap3_thumbnail_EMCchart_mar13.jpg

Our company directory listing provides detailed information on various publicly traded companies including price charts.  You are welcome to use the charting tool and perform your own technical analysis to the price action of the company’s stock. 

Latest Company Financing News:

Organigram Announces Issuance of Stock Options

MONCTON, NEW BRUNSWICK--(Marketwired - March 14, 2017) - Organigram Holdings Inc. (TSX VENTURE:OGI)(OTCQB:OGRMF) ("Organigram" or the "Company") announces that it has issued an aggregate of 1,500,000 incentive stock options to Greg Engel, a director of the Company and the Company's Chief Executive Officer, at an exercise price of $2.36 per share. View Company Directory Listing on #IMJ

Kitrinor Metals Inc. and Scythian Biosciences Inc. Announce Closing of Subscription Receipt Financing of $13,085,000 With Strategic Lead Investment From Aphria Inc.
Scythian Biosciences Inc. is developing a proprietary Cannabinoid combination therapy for the prevention and treatment of concussions and traumatic brain injury

TORONTO, ONTARIO--(Marketwired - March 14, 2017) - NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

Further to the press release dated February 21, 2017, Kitrinor Metals Inc. (TSX VENTURE:KIT) (the "Company") and Scythian Biosciences Inc. ("Scythian"), a company incorporated under the federal laws of Canada, are pleased to announce that Scythian completed an initial tranche of a brokered private placement offering of subscription receipts ("Subscription Receipts") led by Clarus Securities Inc. (the "Lead Agent"), together with Haywood Securities Inc. and Canaccord Genuity Corp. (collectively, the "Agents"), for gross proceeds of C$13,085,000 (the "Offering"). 

GrowGeneration Secures $1,650,000 in Capital From Merida Capital Partners to Continue to Fuel Growth
DENVER, CO--(Marketwired - March 14, 2017) - GrowGeneration Corp. (OTCQB: GRWG)

METATRON (OTC PINK: MRNJ) Announces $1,000,000 Reg A Capital Raise to fund Cannabis & Vaporize, a Secure Chat App
DOVER, DE--(Marketwired - Mar 14, 2017)

 

 

Rate this blog entry:
0
The Medical Benefit of Cannabidiol

Over the last few years we have seen an explosion of companies marketing, branding and selling CBD based products.   The trend to sell these products in the US will continue to grow as it becomes well know that the Cannabidiol from the cannabis plant does have many medical and health benefits.   Many of the CBD based products are sourced from the Hemp plant which makes it easier to sell in the US as most hemp based products can be sold in the US and do not necessarily require FDA approval for sale if marketed as a health supplement and not a medicine.  

There are a number of companies growing hemp and then extracting CBD oils for use in bi-products that are then marketed as health supplements by other companies.  The supply of CBD has seen tremendous growth over the last few years, the brands and products created and marketed by hundreds of companies  does bring a lot of competition to the market.  As more people become aware of CBD and its benefits, we do believe the sales of CBD based products will continue to grow.   However with more competition these companies will see their profit margins get squeezed and many will fail to bring their products to market.  

There are many companies listed on various stock exchanges that participate in product branding and sales of CBD based products.  While many have gained attention from the investment community, we do have to stress that most of them are using the same components for their products and it will be difficult to differentiate their products from others.  The point is, 90% of these companies do not have anything unique in terms of a product offering and many will fail.  If you are going to invest in companies that market and sell CBD based products, make sure they have a great marketing and branding strategy, have strong distribution partners, a proven management team and are well funded.  

The main purpose of this article is to get a better understanding of CBD and Cannabidiol, the investment opportunities and value of CBD will be discussed in the future.

Below is a basic overview of what CBD and Cannabidiol is and the potential health and medical benefits. The exert and infographic below was provided by Monica Bing from http://cannabisowl.com/

Cannabidiol is a major phytocannabinoid and accounts for about 40% of the marijuana plant’s extract. With quite a broad scope of medical applications, it's use is increasing among all populations and countries and research suggests it to be helpful for seizures, anxiety and other ailments.

CBD exerts its actions through a variety of pathways. This non psychoactive component is considered to have a wide scope of potential therapeutic usage. The exact cause for these effects is not clear. But this miracle herb seems to prevent the breakdown of a chemical in the brain that affects pain, mood, and mental function. 

CBD is consumed in a variety of forms including oil, tinctures, edibles, capsules, lotion and even chewing gum by patients. But CBD oils are becoming popular among chronic pain sufferers. This oil also works against convulsions, anxiety, insomnia, and ulcers.

In fact, this oil is the new hope of a cure for those suffering from terminal illnesses. Recent studies report that medical use of this oil can help people find relief from severe health conditions like cancer and chemotherapy treatment, atopic dermatitis, epilepsy, HIV/AIDS.

This ultimate oil is also gaining ground as a viable treatment option for several childhood illnesses and conditions. For some parents, CBD for kids becomes a last option. For many families, CBD is a miracle molecule that allows their children to live normal lives without hospitalisations, doctor visits, dangerous medications, and being stuck indoors. 

The following infographic outlines the utility of Cannabidiol.

b2ap3_thumbnail_cannabidiol1.png

Rate this blog entry:
0
Does The Trump Govt Threaten Recreational Marijuana?

There were always some questions about what a Trump Gov’t would mean to the cannabis industry.  With very little mention of it during the elections and after him taking office, industry participants and companies had no clear indication on what his presidency would mean to the cannabis industry.  Today, comments from press secretary Sean Spicer has shed some light on what their thoughts are on the subject of medical and recreational marijuana.  

While the comments haven’t given a green light for moving forwards with cannabis reforms at the federal level, it does look like the president appreciates medical marijuana laws.  However the recreational marijuana initiatives by various states may come under scrutiny and become questionable under Jeff Sessions at the Dept. of Justice.   The comments below don’t give much indication on what this would mean to the recreational market, but it does create a lot more uncertainty.    The question around the recreational market will be left to the Dept. of Justice and Secretary Sean Spicer does believe there will be greater enforcement around it and the DOJ will be looking into it further.  What “greater enforcement” means to States who have current or planned recreational laws is uncertain, but we are confident they will get more aggressive with the illegal and grey market area when it comes to marijuana sales and use.

Press Briefing by Press Secretary Sean Spicer, 2/23/2017, #15

Q     I have a question on medical marijuana.  Our state voters passed a medical marijuana amendment in November.  Now we're in conflict with federal law, as many other states are.  The Obama administration kind of chose not to strictly enforce those federal marijuana laws.  My question to you is:  With Jeff Sessions over at the Department of Justice as AG, what’s going to be the Trump administration’s position on marijuana legalization where it’s in a state-federal conflict like this?

MR. SPICER:   There’s two distinct issues here: medical marijuana and recreational marijuana.  

I think medical marijuana, I’ve said before that the President understands the pain and suffering that many people go through who are facing especially terminal diseases and the comfort that some of these drugs, including medical marijuana, can bring to them.  And that's one that Congress, through a rider in 2011 -- looking for a little help -- I think put in an appropriations bill saying the Department of Justice wouldn’t be funded to go after those folks.  

There is a big difference between that and recreational marijuana.  And I think that when you see something like the opioid addiction crisis blossoming in so many states around this country, the last thing that we should be doing is encouraging people.  There is still a federal law that we need to abide by in terms of the medical -- when it comes to recreational marijuana and other drugs of that nature.  

So I think there’s a big difference between medical marijuana, which states have a -- the states where it’s allowed, in accordance with the appropriations rider, have set forth a process to administer and regulate that usage, versus recreational marijuana.  That’s a very, very different subject.

Q:  So is the federal government then going to take some sort of action around this recreational marijuana in some of these states?

MR. SPICER:  Well, I think that’s a question for the Department of Justice.  I do believe that you’ll see greater enforcement of it.  Because again, there’s a big difference between the medical use which Congress has, through an appropriations rider in 2014, made very clear what their intent was in terms of how the Department of Justice would handle that issue.  That’s very different than the recreational use, which is something the Department of Justice I think will be further looking into.  

So what does this mean for companies operating in the recreational market?  It surely does create uncertainty and that is something the market doesn’t like.   The cannabis sector has gained much attention over the last year, especially leading up to the US elections and after.  Many of the stock prices has risen significantly over the last 6 months as the industry is anticipating the recreational market will continue to expand in the various states which have moved towards legalization. 

What does this mean for investments in the US related cannabis industry?  We believe that the euphoria in company valuations and the stock price rising as it has over the last 6 months will become subdued.  The sector needs to take a breather and digest the potential outcome of anti-recreational DOJ.  While we remain optimistic on the sector overall, investors should keep in mind the stock prices and valuations probably have gotten ahead of themselves and are likely for a correction.  We will be providing an update to our newsletter subscribers very shortly on what this means to their current and future investment strategies and objectives when it comes marijuana stocks with exposure to US markets.  Sign up for our newsletter to get additional insights and opportunities on the cannabis sector.

Rate this blog entry:
0

Marijuana Stocks haven’t risen much after the U.S. Elections and the win by Donald Trump.
The five states have voted on full legalization, while four other states could legalize medical marijuana.
Here are the results: California, Massachusetts, Maine and Nevada have voted to legalize recreational marijuana in their states, while Arizona rejected its measure.  Four other states — Arkansas, Florida, Montana and North Dakota — passed ballot measures legalizing medical marijuana.    A recent poll suggests a majority of Americans support the legalization of Marijuana, now with these new states voting in favor of marijuana reform and legalization we could be on the way toward a majority of citizens living in a state that allows for some form of legal marijuana.

Rate this blog entry:
0

Canadian Market Overview

The Canadian cannabis sector continues to be blazing hot over the last year, especially in the last 2 months.  The following chart shows the performance of the Canadian marijuana sector in general, the Marijuana Index Canada  contains a list of 10 publicly traded Canadian companies in the space, their stock prices and market caps.  Just looking at this chart, there has been a parabolic rise in share price since May of this year.  Most parabolic rises like this are usually followed by a correction and then a basing period before any further advances can be made.  The chart does show a clear break out and passed overhead resistance, this means we are in a new bull market for cannabis stocks in Canada.  We will provide an update on the American cannabis sector shortly.

Rate this blog entry:
0
Oregon State Guide for Recreational Marijuana Businesses

The following news release was issued by the Oregon Liquor Control Commission, they have provided a guide for potential entrepreneurs and businesses interested in applying for a recreational marijuana license.  If you are considering opening up a marijuana business in Oregon, please reach out to us at www.investinmj.com and contact us if you need assistance in financing, marketing or setting up your commercial grow operation.  We have many contacts in the industry that are very interested in helping you succeed.  We can leverage out contacts with many other commercial marijuana growers to assist you, some of which may even consider a joint venture with you.

We wish you all the best in opening up a marijuana operation in Oregon, these are very exciting times but they do come with some risk, Invest In MJ is here to help you mitigate them.  
IMJ Admin.

 http://www.oregon.gov/olcc/marijuana/Documents/BusinessReadinessGuide_RecreationalMarijuana.pdf

State Produces Guide for Recreational Marijuana Businesses

Designed to Help Navigate State and Local Government Requirements

November 20, 2015

Portland, Oregon – The Oregon Liquor Control Commission has released a “Business Readiness Guidebook for Oregon Recreational Marijuana Operations” for individuals interested in applying for a recreational marijuana license.  The guidebook was produced under the guidance of Governor Kate Brown’s office, with contributions from more than a dozen state agencies that directly regulate the marijuana industry or regulate business.

“Obtaining a license from the OLCC is just one step to establishing a marijuana related business,” said Steve Marks, Executive Director of the OLCC.  “The OLCC wants to help this industry become successful and compliant, and having this guide to help navigate the business regulatory process is an important component of that effort.”

From building codes to odor control, from waste management to workplace safety, the Business Readiness Guidebook provides an overview of the rules and requirements within the larger regulatory framework under which all businesses in Oregon must operate.

By pointing to where up-to-date state and local information can be found the OLCC expects the guide will help businesses be better prepared to establish legal recreational marijuana operations in Oregon and comply with state and local law.

The “Business Readiness Guidebook for Oregon Recreational Marijuana Operations” can be found on the OLCC website and will be updated with current information as it becomes available.

For more information:
Mark Pettinger, Spokesperson
Mark.pettinger@oregon.gov  (503) 872-5115
www.marijuana.oregon.gov

Rate this blog entry:
0
Recent Comments - Show all comments
  • Fred Brown
    Fred Brown says #
    While recreational pot usage is controversial, many people agree and believe that the drug should be legal for medical uses. Onlin
  • Kaylee Ward
    Kaylee Ward says #
    Thoughtful blog post . I loved the points ! Does anyone know if my company could possibly access a fillable Lex Homeowners/Dwellin
  • Kaylee Ward
    Kaylee Ward says #
    Thoughtful blog post . I loved the points ! Does anyone know if my company could possibly access a fillable Lex Homeowners/Dwellin
US Govt Owns The Patent On Some Cannabis Cures

Could it be true, does the U.S. Government own a patent on some Cannabis Cures?  

Yes it does seem like this is a reality.  

Marijuana remains a scheduled I drug and is included with the likes of heroin, LSD, ecstasy, meth and peyote.  Thus Cannabis has been classified as having a "high potential for abuse" and having "no currently accepted medical use'.  Ironically, there is a patent for "Cannabinoids as antioxidants and neuroprotectants" which has be in effect since October 7, 2003 and it is assigned to none other than... you guessed it,  The United States of America as represented by the Department of Health and Human Services (Washington, DC).

So while maintaining the stance that Cannabis is harmful to our health and has no medicinal value, the corporation of The United States of America over a decade ago has been assigned the patent for cannabis as a antioxidants and neuroprotectants.  Here is the Abstract about the patent:

Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH.sub.3, and COCH.sub.3. ##STR1## 

If you are interested in reading more about this patent and what it entails, here is the link to United States Patent # 6630507, Cannabinoids as antioxidants and neuroprotectants

What are your thoughts, should the United State of America have he rights to this patent?

b2ap3_thumbnail_cannabis_patent_by_USgovt.jpg

Rate this blog entry:
0
Tweed Acquires MedCannAccess and Opens Dispensaries in Ontario

Tweed, one of Canada's first medical cannabis producers, recently renamed Canopy Growth Corporation, has opened a dispensary in Guelph. The storefront now known as Better by Tweed, opened Oct. 15 and is the town’s first dispensary.

In September, Tweed purchased MedCannAccess a company focused on helping new medical marijuana patients and acquired the group’s three community access centres in Guelph, Hamilton and the Greater Toronto Area. The Hamilton location opened earlier in the week and Better by Tweed will soon expand with the Etobicoke Better Centre. 

The MedCannAccess locations had helped cannabis patients register with a licensed producer.

The Better by Tweed operation will provide patients with information packages to bring to their doctors to fill out and then return to the store where they can place orders for cannabis from Tweed’s production facilities in Smiths Falls, Toronto and Niagara-on-the-Lake.

“There will always be a market for medical marijuana, and, if the time comes, we’re well equipped for recreational use as well,” said Tweed president Mark Zekulin.

Rate this blog entry:
0

The Drug Enforcement Administration (DEA) is proposing to adjust the established 2015 aggregate production quota for marijuana.  While marijuana is a scheduled I drug and the laws around it are enforced by the DEA, they do allow several government agencies and registered manufacturers to produce it for research and product development.

Registered manufacturers and the National Institute on Drug Abuse (NIDA) have requested a higher quota for production and supply of marijuana for 2015.  The previous 2015 established quote for marijuana was 125,000 g, and the new adjusted quota for 2015 is 400,000 g.

DEA-police.jpg

Highlights from the Federal Register Notice:

Background:

The DEA established the initial 2015 aggregate production quotas and assessments of annual need on September 8, 2014 (79 FR 53216). That notice stipulated that, as provided for in 21 CFR 1303.13, all aggregate production quotas and assessments of annual need are subject to adjustment.

Based on unanticipated medical, scientific, research, and industrial needs of the United States the DEA proposes to adjust the established 2015 aggregate production quotas for the schedule I and II controlled substances difenoxin, diphenoxylate (for conversion), and marijuana to be manufactured in the United States in 2015. The adjustment is necessary to provide for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stocks.

In proposing the adjustment, the Administrator has taken into account the following criteria in accordance with 21 CFR 1303.13: (1) Changes in demand for the basic class, changes in the national rate of net disposal for the class, and changes in the rate of net disposal by the registrants holding individual manufacturing quotas for the class; (2) whether any increased demand or changes in the national and/or individual rates of net disposal are temporary, short term, or long term; (3) whether any increased demand for that class can be met through existing inventories, increased individual manufacturing quotas, or increased importation, without increasing the aggregate production quota; (4) whether any decreased demand will result in excessive inventory accumulation by all persons registered to handle the class; and (5) other factors affecting the medical, scientific, research, and industrial needs of the United States and lawful export requirements, as the Administrator finds relevant.

Analysis for Adjusting the Established 2015 Aggregate Production Quota for Marijuana:

Since the establishment of the initial 2015 aggregate production quotas, the DEA has received notification from DEA registered manufacturers that research and product development involving cannabidiol, is increasing beyond that previously anticipated for 2015. The associated product development activities are related to process validation and commercialization activities, including qualification activities related to potential U.S. Food and Drug Administration submission support.

Additionally, the DEA has also received notification from the National Institute on Drug Abuse (NIDA) that it required additional supplies of marijuana to be manufactured in 2015 to provide for ongoing and anticipated research efforts involving marijuana. NIDA is a component of the National Institutes of Health and the U.S. Department of Health and Human Services which oversees the cultivation, production and distribution of research-grade marijuana on behalf of the United States Government, pursuant to the Single Convention on Narcotic Drugs (March 30, 1961, 18 UST 1407).

The Administrator Michele M. Leonhart, therefore, proposes to adjust the 2015 aggregate production quotas for difenoxin, diphenoxylate (for conversion), and marijuana, expressed in grams of anhydrous acid or base.

You can read the full Notice by the DEA and provide your opinion as they are requesting comments.

Sign up for our newsletter to get the latest marijuana industry news and opportunities sent to you directly.

{loadposition imjnews}

Rate this blog entry:
0

Select Your Language

enzh-CNnlfrdehies